DDInter1397 DDInter1925
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
Paroxetine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Paroxetine {u} (Compound) upregulates {v} (Gene) NFIL3
NFIL3 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Paroxetine {u} (Compound) downregulates {v} (Gene) BRCA1
BRCA1 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Paroxetine {u} (Compound) upregulates {v} (Gene) MSMO1
MSMO1 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Paroxetine {u} (Compound) downregulates {v} (Gene) DNTTIP2
DNTTIP2 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Paroxetine {u} (Compound) causes {v} (Side Effect) Eosinophilia
Eosinophilia {u} (Side Effect) is caused by {v} (Compound) Vemurafenib
Paroxetine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Vemurafenib
Paroxetine {u} (Compound) upregulates {v} (Gene) NFIL3
NFIL3 {u} (Gene) is regulated by {v} (Gene) IKZF1
IKZF1 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Paroxetine {u} (Compound) upregulates {v} (Gene) SARS
SARS {u} (Gene) regulates {v} (Gene) CRIP1
CRIP1 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Paroxetine {u} (Compound) downregulates {v} (Gene) BRCA1
BRCA1 {u} (Gene) regulates {v} (Gene) CRIP1
CRIP1 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Paroxetine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Vemurafenib (Compound)
Paroxetine (Compound) upregulates NFIL3 (Gene) and NFIL3 (Gene) is upregulated by Vemurafenib (Compound)
Paroxetine (Compound) downregulates BRCA1 (Gene) and BRCA1 (Gene) is upregulated by Vemurafenib (Compound)
Paroxetine (Compound) upregulates MSMO1 (Gene) and MSMO1 (Gene) is downregulated by Vemurafenib (Compound)
Paroxetine (Compound) downregulates DNTTIP2 (Gene) and DNTTIP2 (Gene) is downregulated by Vemurafenib (Compound)
Paroxetine (Compound) causes Eosinophilia (Side Effect) and Eosinophilia (Side Effect) is caused by Vemurafenib (Compound)
Paroxetine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vemurafenib (Compound)
Paroxetine (Compound) upregulates NFIL3 (Gene) and NFIL3 (Gene) is regulated by IKZF1 (Gene) and IKZF1 (Gene) is upregulated by Vemurafenib (Compound)
Paroxetine (Compound) upregulates SARS (Gene) and SARS (Gene) regulates CRIP1 (Gene) and CRIP1 (Gene) is upregulated by Vemurafenib (Compound)
Paroxetine (Compound) downregulates BRCA1 (Gene) and BRCA1 (Gene) regulates CRIP1 (Gene) and CRIP1 (Gene) is upregulated by Vemurafenib (Compound)